ResponseVerdict Overturns Validated Immunotherapy Signatures and Recovers Missed Responders
Start here
A computational tool called ResponseVerdict reorients immunotherapy response signatures by using measured responses from other treated patient cohorts rather than relying on conventional validation. In a study posted to bioRxiv on 22 October 2026, it was evaluated across 2,045 patients, where it raised AUROC by 0.14 compared with TIDE, and in 2,000 paired comparisons it significantly outperformed published predictors in 1,178. The work claims to overturn computationally validated signatures, recover patients those signatures missed as responders, and beat every published response predictor tested. What remains open is peer review, independent replication on additional cohorts, and whether the approach changes how signatures are selected for clinical use.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- biorxiv.orgResponseVerdict overturns computationally validated immunotherapy signatures, recovers their missed responders and outperforms every published response predictor
ResponseVerdict reorients immunotherapy response signatures using measured responses in other treated cohorts. Across 2,045 patients it raises AUROC by 0.14 over TIDE, and in 2,000 paired comparisons it is significantly better than published predictors in 1,178 of them.
Heat trend for this story
Heat now 7·Peak in the comparable set 7 (Oct 22 21:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.